| Mark D Anderson, MD | |
|
3801 S National Ave, Springfield, MO 65807-5210 | |
| (417) 875-3000 | |
| Not Available |
| Full Name | Mark D Anderson |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 41 Years |
| Location | 3801 S National Ave, Springfield, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073557922 | NPI | - | NPPES |
| 201523107 | Medicaid | MO | |
| 107049 | Other | BLUE CROSS/BLUE SHIELD | |
| 203008701 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 36539 (Missouri) | Secondary |
| 207RI0011X | Internal Medicine - Interventional Cardiology | 36539 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cox Medical Centers | Springfield, MO | Hospital |
| Cox Monett Hospital | Monett, MO | Hospital |
| Texas County Memorial Hospital | Houston, MO | Hospital |
| Citizens Memorial Hospital | Bolivar, MO | Hospital |
| Cox Medical Center Branson | Branson, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cox-monett Hospital Inc | 0345236667 | 50 |
| Lester E Cox Medical Centers | 1254248917 | 262 |
News Archive
With the cost of drugs a critical issue in health care, health insurance companies and government payers need to understand how new and existing drugs compare in terms of benefits and risks.
Using a combination of "Jeopardy," "Saturday Night Live" and a famous Discovery Channel show called MythBusters, patient advocates and researchers at Vanderbilt Ingram Cancer Center presented "Mythbusters: Cancer Research in Jeopardy" to their community in an effort to increase awareness of cancer research, particularly clinical trials.
Battling the COVID-19 pandemic and preparing for the inevitable next surge requires a data-driven population health approach.
The National Eye Institute has awarded researchers at the Schepens Eye Research Institute, a subsidiary of Mass. Eye and Ear, a five year-grant totaling more than $2.4 million to understand the origins of eye allergies.
The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma.
› Verified 6 days ago
| Entity Name | Cox-monett Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669687125 PECOS PAC ID: 0345236667 Enrollment ID: O20040521000080 |
News Archive
With the cost of drugs a critical issue in health care, health insurance companies and government payers need to understand how new and existing drugs compare in terms of benefits and risks.
Using a combination of "Jeopardy," "Saturday Night Live" and a famous Discovery Channel show called MythBusters, patient advocates and researchers at Vanderbilt Ingram Cancer Center presented "Mythbusters: Cancer Research in Jeopardy" to their community in an effort to increase awareness of cancer research, particularly clinical trials.
Battling the COVID-19 pandemic and preparing for the inevitable next surge requires a data-driven population health approach.
The National Eye Institute has awarded researchers at the Schepens Eye Research Institute, a subsidiary of Mass. Eye and Ear, a five year-grant totaling more than $2.4 million to understand the origins of eye allergies.
The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma.
› Verified 6 days ago
| Entity Name | Skaggs Community Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861423683 PECOS PAC ID: 5092624320 Enrollment ID: O20040811000689 |
News Archive
With the cost of drugs a critical issue in health care, health insurance companies and government payers need to understand how new and existing drugs compare in terms of benefits and risks.
Using a combination of "Jeopardy," "Saturday Night Live" and a famous Discovery Channel show called MythBusters, patient advocates and researchers at Vanderbilt Ingram Cancer Center presented "Mythbusters: Cancer Research in Jeopardy" to their community in an effort to increase awareness of cancer research, particularly clinical trials.
Battling the COVID-19 pandemic and preparing for the inevitable next surge requires a data-driven population health approach.
The National Eye Institute has awarded researchers at the Schepens Eye Research Institute, a subsidiary of Mass. Eye and Ear, a five year-grant totaling more than $2.4 million to understand the origins of eye allergies.
The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma.
› Verified 6 days ago
| Entity Name | Lester E Cox Medical Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538334396 PECOS PAC ID: 1254248917 Enrollment ID: O20050624000293 |
News Archive
With the cost of drugs a critical issue in health care, health insurance companies and government payers need to understand how new and existing drugs compare in terms of benefits and risks.
Using a combination of "Jeopardy," "Saturday Night Live" and a famous Discovery Channel show called MythBusters, patient advocates and researchers at Vanderbilt Ingram Cancer Center presented "Mythbusters: Cancer Research in Jeopardy" to their community in an effort to increase awareness of cancer research, particularly clinical trials.
Battling the COVID-19 pandemic and preparing for the inevitable next surge requires a data-driven population health approach.
The National Eye Institute has awarded researchers at the Schepens Eye Research Institute, a subsidiary of Mass. Eye and Ear, a five year-grant totaling more than $2.4 million to understand the origins of eye allergies.
The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma.
› Verified 6 days ago
| Entity Name | Skaggs Community Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346602646 PECOS PAC ID: 5092624320 Enrollment ID: O20160517000289 |
News Archive
With the cost of drugs a critical issue in health care, health insurance companies and government payers need to understand how new and existing drugs compare in terms of benefits and risks.
Using a combination of "Jeopardy," "Saturday Night Live" and a famous Discovery Channel show called MythBusters, patient advocates and researchers at Vanderbilt Ingram Cancer Center presented "Mythbusters: Cancer Research in Jeopardy" to their community in an effort to increase awareness of cancer research, particularly clinical trials.
Battling the COVID-19 pandemic and preparing for the inevitable next surge requires a data-driven population health approach.
The National Eye Institute has awarded researchers at the Schepens Eye Research Institute, a subsidiary of Mass. Eye and Ear, a five year-grant totaling more than $2.4 million to understand the origins of eye allergies.
The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark D Anderson, MD Po Box 9007, Springfield, MO 65808-9007 Ph: () - | Mark D Anderson, MD 3801 S National Ave, Springfield, MO 65807-5210 Ph: (417) 875-3000 |
News Archive
With the cost of drugs a critical issue in health care, health insurance companies and government payers need to understand how new and existing drugs compare in terms of benefits and risks.
Using a combination of "Jeopardy," "Saturday Night Live" and a famous Discovery Channel show called MythBusters, patient advocates and researchers at Vanderbilt Ingram Cancer Center presented "Mythbusters: Cancer Research in Jeopardy" to their community in an effort to increase awareness of cancer research, particularly clinical trials.
Battling the COVID-19 pandemic and preparing for the inevitable next surge requires a data-driven population health approach.
The National Eye Institute has awarded researchers at the Schepens Eye Research Institute, a subsidiary of Mass. Eye and Ear, a five year-grant totaling more than $2.4 million to understand the origins of eye allergies.
The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma.
› Verified 6 days ago
Dr. Mark H. Grimm, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 3231 S National Ave, Springfield, MO 65807 Phone: 417-888-5696 Fax: 417-888-6711 | |
Dr. Sridevi Durga, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3800 S National Ave, Suite 400, Springfield, MO 65807 Phone: 417-875-2633 Fax: 417-875-3295 | |
Bradley D Wiley, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1001 E Primrose St, Springfield, MO 65807 Phone: 417-875-3000 Fax: 417-875-3051 | |
Walter S. Trombold, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6044 S Overlook Trl, Springfield, MO 65810 Phone: 417-771-5778 | |
Dr. Timi A Akins, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4814 S Montrose Pl, Springfield, MO 65810 Phone: 202-779-1247 | |
Ghulam Jeelani Siddiqui, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2115 S Fremont Ave, Suite 3300, Springfield, MO 65804 Phone: 417-820-5200 Fax: 417-820-5220 | |
Danny R Penick, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3801 S National Ave, Springfield, MO 65807 Phone: 417-269-0000 |